Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).

In the present multicentre randomized phase II trial, the activity and toxicity of three platinum-based combination regimens for the treatment of advanced non-small-cell lung cancer (NSCLC) were evaluated. The three regimens were: MVP (mitomycin-C 6 mg m(-2) on day 1, vindesine 3 mg m(-2) on days 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldini, E., Tibaldi, C., Ardizzoni, A., Salvati, F., Antilli, A., Portalone, L., Barbera, S., Romano, F., De Marinis, F., Migliorino, M. R., Noseda, M. A., Borghini, U., Crippa, M., Ferrara, G., Raimondi, M., Fioretti, M., Bandera, M., Pennucci, M. C., Galeasso, G., Cacciani, G. C., Lepidini, G., Sunseri, G., Lanfranco, C., Rinaldi, M., Rosso, R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150421/
https://www.ncbi.nlm.nih.gov/pubmed/9649160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150421/
https://www.ncbi.nlm.nih.gov/pubmed/9649160

Ejemplares similares